Development of a travelers' diarrhea vaccine for the military: How much is an ounce of prevention really worth?

Vaccine

Volumn 26, Issue 20, 2008, Pages 2490-2502

  Riddle, Mark S ^a   Tribble, David R ^a   Cachafiero, Santiago Pérez ^b   Putnam, Shannon D ^c   Hooper, Tomoko I ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

Author keywords

Economic analysis; Research prioritization; Travelers' diarrhea

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; ESCHERICHIA COLI VACCINE; LOPERAMIDE; SHIGELLA VACCINE;

ANTIBIOTIC THERAPY; ARMY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TRAVELLER DIARRHEA; VACCINATION;

BACTERIAL VACCINES; COST OF ILLNESS; DIARRHEA; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI VACCINES; HUMANS; MILITARY PERSONNEL; SHIGELLA VACCINES;

EID: 42649142899     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.008     Document Type: Article

References (68)

1. Lemon SM, Thaul, S, Fisseha, S, O'Maonaigh, HC. Protecting our forces: improving vaccine acquisition and availability in the U.S. military. IOM report. Washington, DC: Institute of Medicine of the National Academies; 2003.
2. Vaughn D. Military infectious disease research program. Director's program briefing; 2006 [cited; available from: http://www.midrp.org/pdf_files/PPBD/01%20MIDRP%20overview%20v02%2011Apr06.pdf].
3. Taylor D.N., Sanchez J.L., Candler W., Thornton S., McQueen C., and Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 114 9 (1991) 731-734
4. Scott D.A., Haberberger R.L., Thornton S.A., and Hyams K.C. Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am J Trop Med Hyg 42 2 (1990) 160-164
5. De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers' diarrhoea. Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD002242. doi:10.1002/14651858.CD002242.
6. Guerrant R.L., Van Gilder T., Steiner T.S., Thielman N.M., Slutsker L., Tauxe R.V., et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32 3 (2001) 331-351
7. Wingate D., Phillips S.F., Lewis S.J., Malagelada J.R., Speelman P., Steffen R., et al. Guidelines for adults on self-medication for the treatment of acute diarrhoea. Aliment Pharmacol Ther 15 6 (2001) 773-782
8. Travelers' Diarrhea. NIH Consensus Statement Online 1985 Jan 28-30 [cited 21 September 2007]; 5(8):1-19.
9. Riddle M.S., Sanders J.W., Putnam S.D., and Tribble D.R. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. Am J Trop Med Hyg 74 5 (2006) 891-900
10. Kitchen L.W., Vaughn D.W., and Skillman D.R. Role of US military research programs in the development of US Food and Drug Administration-approved antimalarial drugs. Clin Infect Dis 43 1 (2006) 67-71
11. Artenstein A.W., Opal J.M., Opal S.M., Tramont E.C., Peter G., and Russell P.K. History of U.S. military contributions to the study of vaccines against infectious diseases. Mil Med 170 Suppl. 4 (2005) 3-11
12. Worldwide manpower distribution by geographical area. Personnel and procurement reports and data files. Department of Defense, Defense Manpower Data Center; September 2005. [cited; available from: http://siadapp.dmdc.osd.mil/personnel/Pubs.htm#M05].
13. Hosek JR, Totten M. United States Department of Defense. Office of the Secretary of Defense, National Defense Research Institute (U.S.). Does perstempo hurt reenlistment? The effect of long or hostile perstempo on reenlistment. Santa Monica, CA: RAND; 1998.
14. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., and Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17 Suppl. 2 (1999) S22-S27
15. Sack D.A., Clemens J.D., Huda S., Harris J.R., Khan M.R., Chakraborty J., et al. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 164 2 (1991) 407-411
16. Jose M.V., and Bobadilla J.R. Epidemiological model of diarrhoeal diseases and its application in prevention and control. Vaccine 12 2 (1994) 109-116
17. Abu-Elyazeed R., Wierzba T.F., Mourad A.S., Peruski L.F., Kay B.A., Rao M., et al. Epidemiology of enterotoxigenic Escherichia coli diarrhea in a pediatric cohort in a periurban area of lower Egypt. J Infect Dis 179 2 (1999) 382-389
18. Isenbarger D.W., Bodhidatta L., Hoge C.W., Nirdnoy W., Pitarangsi C., Umpawasiri U., et al. Prospective study of the incidence of diarrheal disease and Helicobacter pylori infection among children in an orphanage in Thailand. Am J Trop Med Hyg 59 5 (1998) 796-800
19. Herwaldt B.L., de Arroyave K.R., Roberts J.M., and Juranek D.D. A multiyear prospective study of the risk factors for and incidence of diarrheal illness in a cohort of Peace Corps volunteers in Guatemala. Ann Intern Med 132 12 (2000) 982-988
20. Report of the quadrennial defense review. United States Department of Defense; 2006.
21. Monteville M.R., Riddle M.S., Baht U., Putnam S.D., Frenck R.W., Brooks K., et al. Incidence, etiology, and impact of diarrhea among deployed U.S. military personnel in support of operation Iraqi freedom and operation enduring freedom. Am J Trop Med Hyg 75 4 (2006) 762-767
22. Sanders J.W., Isenbarger D., Walz S., Pang L.W., Scott D.A., Tamminga C., et al. An observational clinic-based study of diarrheal illness in deployed U.S. military personnel in Thailand: presentation and outcome of Campylobacter infection. 49th annual meeting of the American Society of Tropical Medicine and Hygiene. Washington, DC (1999)
23. Sanders J.W., Isenbarger D.W., Walz S.E., Pang L.W., Scott D.A., Tamminga C., et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg 67 5 (2002) 533-538
24. Sanders J.W., Putnam S.D., Gould P., Kolisnyk J., Merced N., Barthel V., et al. Diarrheal illness among deployed U.S. military personnel during Operation Bright Star 2001-Egypt. Diagn Microbiol Infect Dis 52 2 (2005) 85-90
25. Sanders J.W., Putnam S.D., Riddle M.S., Tribble D.R., Jobanputra N.K., Jones J.J., et al. The epidemiology of self-reported diarrhea in operations Iraqi freedom and enduring freedom. Diagn Microbiol Infect Dis 50 2 (2004) 89-93
26. Top FH, Dingerdissen JJ, Habig WH, Quinnan GV, Wells RL. DoD Acquisition of vaccine production. Report to the Secretary of Defense by the Independent Panel of Experts, December 2000. In DoD, 2001 report on biological warfare defense vaccine research and development programs. Washington, DC: Department of Defense [Online; available: http://www.acq.osd.mil/cp/bwdvrdp-july01.pdf].
27. Greco M. Development and supply of vaccines: an industry perspective. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New generation vaccines. 3rd ed. (2004), Marcel Dekker Inc., New York 75-87
28. Riddle M.S., and Tribble D.R. Reaching a consensus on management practices and vaccine development targets for mitigation of infectious diarrhea among deployed U.S. military forces. J Eval Clin Pract 14 2 (2008) 266-274
29. Struck M.M. Vaccine R&D success rates and development times. Nat biotechnol 14 5 (1996) 591-593
30. Department of Defense. DoD vaccine price list, updated 22 September 2006 [retrieved from http://www.vaccines.army.mil/documents/888PriceList.pdf, 19 October 2006].
31. Vold Pepper P., and Owens D.K. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin Infect Dis 30 1 (2000) 157-164
32. Hyer R.N., Howell M.R., Ryan M.A., and Gaydos J.C. Cost-effectiveness analysis of reacquiring and using adenovirus types 4 and 7 vaccines in naval recruits. Am J Trop Med Hyg 62 5 (2000) 613-618
33. Pickering L.K. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 15 2 (2004) 71-77
34. Putnam S.D., Sanders J.W., Frenck R.W., Monteville M., Riddle M.S., Rockabrand D.M., et al. Self-reported description of diarrhea among military populations in operations Iraqi freedom and enduring freedom. J Travel Med 13 2 (2006) 92-99
35. Hill D.R. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg 62 5 (2000) 585-589
36. Mattila L. Clinical features and duration of traveler's diarrhea in relation to its etiology. Clin Infect Dis 19 4 (1994) 728-734
37. Sanders J.W., Frenck R.W., Putnam S.D., Riddle M.S., Johnston J.R., Ulukan S., et al. Azithromycin and loperamide is comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in U.S. military personnel in Turkey. Annual meeting of the Infectious Diseases Society of America. San Fransisco, CA (2005) [abstract 301]
38. Adachi J.A., Ericsson C.D., Jiang Z.D., DuPont M.W., Martinez-Sandoval F., Knirsch C., et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 37 9 (2003) 1165-1171
39. De Bruyn G., Hahn S., and Borwick A. Antibiotic treatment for travellers' diarrhoea. Cochrane Database Syst Rev 3 (2000) CD002242
40. Diemert D.J. Prevention and self-treatment of traveler's diarrhea. Clin Microbiol Rev 19 3 (2006) 583-594
41. DuPont H.L., Reves R.R., Galindo E., Sullivan P.S., Wood L.V., and Mendiola J.G. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 307 14 (1982) 841-844
42. DuPont H.L., Ericsson C.D., Mathewson J.J., and DuPont M.W. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob Agents Chemother 36 1 (1992) 87-91
43. Hyams K.C., Bourgeois A.L., Merrell B.R., Rozmajzl P., Escamilla J., Thornton S.A., et al. Diarrheal disease during Operation Desert Shield. N Engl J Med 325 20 (1991) 1423-1428
44. Kuschner R.A., Trofa A.F., Thomas R.J., Hoge C.W., Pitarangsi C., Amato S., et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 21 3 (1995) 536-541
45. Tribble D.R., Sanders J.W., Pang L.W., Mason C., Pitarangsi C., Baqar S., et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 44 3 (2007) 338-346
46. Congressional Budget Office. Estimated costs of a potential conflict with Iraq; 2002 [accessed online from http://www.cbo.gov/ftpdocs/38xx/doc3822/09-30-Iraq.pdf on March 23, 2007].
47. Matson D.O. Norovirus gastroenteritis in US Marines in Iraq. Clin Infect Dis 40 4 (2005) 526-527
48. National Intelligence Council. The global infectious disease threat and its implications for the United States. NIE-99-17D; 2000.
49. Taylor W. Business case analysis for an ETEC vaccine. The 4th international conference on vaccines for enteric diseases. Lisbon, Portugal (2007)
50. McCarthy N., and Giesecke J. Incidence of Guillain-Barre syndrome following infection with Campylobacter jejuni. Am J Epidemiol 153 6 (2001) 610-614
51. Hill Gaston J.S., and Lillicrap M.S. Arthritis associated with enteric infection. Best Pract Res Clin Rheumatol 17 2 (2003) 219-239
52. Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum; March 2007.
53. Rees J.R., Pannier M.A., McNees A., Shallow S., Angulo F.J., and Vugia D.J. Persistent diarrhea, arthritis, and other complications of enteric infections: a pilot survey based on California FoodNet surveillance, 1998-1999. Clin Infect Dis 38 Suppl. 3 (2004) S311-S317
54. Garcia Rodriguez L.A., Ruigomez A., and Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 130 6 (2006) 1588-1594
55. Halvorson H.A., Schlett C.D., and Riddle M.S. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 101 8 (2006) 1894-1899 [quiz 942]
56. Rhodes D.Y., and Wallace M. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 8 4 (2006) 327-332
57. Amouretti M., Le Pen C., Gaudin A.F., Bommelaer G., Frexinos J., Ruszniewski P., et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol 30 2 (2006) 241-246
58. ten Berg M.J., Goettsch W.G., van den Boom G., Smout A.J., and Herings R.M. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol 18 5 (2006) 475-481
59. Quigley E.M., Bytzer P., Jones R., and Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 38 10 (2006) 717-723
60. Maxion-Bergemann S., Thielecke F., Abel F., and Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 24 1 (2006) 21-37
61. Dean B.B., Aguilar D., Barghout V., Kahler K.H., Frech F., Groves D., et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 11 Suppl. 1 (2005) S17-S26
62. Cash B., Sullivan S., and Barghout V. Total costs of IBS: employer and managed care perspective. Am J Manag Care 11 Suppl. 1 (2005) S7-S16
63. Cash B. Economic impact of irritable bowel syndrome: what does the future hold?. Am J Manag Care 11 Suppl. 1 (2005) S4-S6
64. Payls T.G.S. XXth annual meeting of the American Society of Tropical Medicine and Hygiene. Philadelphia, PA (2007)
65. Defense Health Care. Quality assurance process needed to improve force health protection and surveillance. United States General Accounting Office, GAO-03-1041; 2003.
66. Sanders J.W., Putnam S.D., Frankart C., Frenck R.W., Monteville M.R., Riddle M.S., et al. Impact of illness and non-combat injury during Operations Iraqi Freedom and Enduring Freedom (Afghanistan). Am J Trop Med Hyg 73 4 (2005) 713-719
67. Riddle M.S., Tribble D.R., Jobanputra N.K., Jones J.J., Putnam S.D., Frenck R.W., et al. Knowledge, attitudes, and practices regarding epidemiology and management of travelers' diarrhea: a survey of front-line providers in Iraq and Afghanistan. Mil Med 170 6 (2005) 492-495
68. Cohen D., Sela T., Slepon R., Yavzori M., Ambar R., Orr N., et al. Prospective cohort studies of Shigellosis during military field training. Eur J Clin Microbiol Infect Dis 20 2 (2001) 123-126